Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice

Masaki Magari; Mika Ikeda; Miki Asakura; Naoki Kanayama; Masami Ogawa; Hitoshi Ohmori

doi:10.1080/08923970600928155

Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice

Masaki Magari, Mika Ikeda, Miki Asakura, Naoki Kanayama, Masami Ogawa, Hitoshi Ohmori

Research output: Contribution to journal › Article

1 Citation (Scopus)

Abstract

A nasal formulation of mometasone furoate (MF) is advantageous in avoiding systemic activity characteristic of glucocorticoids when it is applied topically. To confirm antiallergic effects of this glucocorticoid formulation elaborately, we investigated whether the drug can suppress the production of IgE antibodies and related cytokines. It we showed that IgE production induced in mice immunized via intranasal route was significantly reduced when the mice were administered MF intranasally. Further, MF was effective in inhibiting production of type-2 helper T cell cytokines in vivo and in vitro. These results provide a immunopharmacological basis for clinical efficacy of this drug.

Original language	English
Pages (from-to)	491-500
Number of pages	10
Journal	Immunopharmacology and Immunotoxicology
Volume	28
Issue number	3
DOIs	https://doi.org/10.1080/08923970600928155
Publication status	Published - Sep 1 2006

Fingerprint

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Toxicology
Pharmacology

Cite this

Magari, M., Ikeda, M., Asakura, M., Kanayama, N., Ogawa, M., & Ohmori, H. (2006). Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice. Immunopharmacology and Immunotoxicology, 28(3), 491-500. https://doi.org/10.1080/08923970600928155

@article{d0fbcc845969411fa7327c268e78f7dd,

title = "Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice",

abstract = "A nasal formulation of mometasone furoate (MF) is advantageous in avoiding systemic activity characteristic of glucocorticoids when it is applied topically. To confirm antiallergic effects of this glucocorticoid formulation elaborately, we investigated whether the drug can suppress the production of IgE antibodies and related cytokines. It we showed that IgE production induced in mice immunized via intranasal route was significantly reduced when the mice were administered MF intranasally. Further, MF was effective in inhibiting production of type-2 helper T cell cytokines in vivo and in vitro. These results provide a immunopharmacological basis for clinical efficacy of this drug.",

author = "Masaki Magari and Mika Ikeda and Miki Asakura and Naoki Kanayama and Masami Ogawa and Hitoshi Ohmori",

year = "2006",

month = sep

day = "1",

doi = "10.1080/08923970600928155",

language = "English",

volume = "28",

pages = "491--500",

journal = "Immunopharmacology and Immunotoxicology",

issn = "0892-3973",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice

AU - Magari, Masaki

AU - Ikeda, Mika

AU - Asakura, Miki

AU - Kanayama, Naoki

AU - Ogawa, Masami

AU - Ohmori, Hitoshi

PY - 2006/9/1

Y1 - 2006/9/1

N2 - A nasal formulation of mometasone furoate (MF) is advantageous in avoiding systemic activity characteristic of glucocorticoids when it is applied topically. To confirm antiallergic effects of this glucocorticoid formulation elaborately, we investigated whether the drug can suppress the production of IgE antibodies and related cytokines. It we showed that IgE production induced in mice immunized via intranasal route was significantly reduced when the mice were administered MF intranasally. Further, MF was effective in inhibiting production of type-2 helper T cell cytokines in vivo and in vitro. These results provide a immunopharmacological basis for clinical efficacy of this drug.

AB - A nasal formulation of mometasone furoate (MF) is advantageous in avoiding systemic activity characteristic of glucocorticoids when it is applied topically. To confirm antiallergic effects of this glucocorticoid formulation elaborately, we investigated whether the drug can suppress the production of IgE antibodies and related cytokines. It we showed that IgE production induced in mice immunized via intranasal route was significantly reduced when the mice were administered MF intranasally. Further, MF was effective in inhibiting production of type-2 helper T cell cytokines in vivo and in vitro. These results provide a immunopharmacological basis for clinical efficacy of this drug.

UR - http://www.scopus.com/inward/record.url?scp=33748994820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748994820&partnerID=8YFLogxK

U2 - 10.1080/08923970600928155

DO - 10.1080/08923970600928155

M3 - Article

C2 - 16997797

AN - SCOPUS:33748994820

VL - 28

SP - 491

EP - 500

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 3

ER -

Access to Document

10.1080/08923970600928155